Profhilo is an injectable hyaluronic acid product from IBSA that combines high- and low-molecular-weight HA. It has been studied for changes in skin characteristics such as hydration and texture. It is not a cream or a name for every HA treatment. Profhilo and Profhilo Structura are different formulations, so the full product name matters before comparing results. Manufacturer’s Profhilo leaflet.
For someone considering treatment, the useful question is specific: what change is being proposed, in which area, and what evidence supports it?
Profhilo and Profhilo Structura: what is different?
The table describes public manufacturer documents. It does not establish the product’s current authorization in Mexico or identify the presentation that would be used in your treatment.
| Product | What its documentation describes | A useful question |
|---|---|---|
| Profhilo | An HA formulation for intradermal use, with face and neck laxity remodeling among its listed indications. | Is the goal a change in skin quality or a particular contour? |
| Profhilo Structura | A different HA formulation whose instructions include intradermal/subcutaneous use and refer to facial adipose tissue. | Which tissue and intended change explain choosing this formulation? |
Sources: Profhilo leaflet, published by IBSA Italy and Structura leaflet, hosted by IBSA Australia.
Sharing a brand or ingredient does not make them interchangeable. Both documents also describe a corrective or filling action on skin depressions, so “neither can have a filling effect” is too absolute. That wording does not make either product equivalent to every gel selected for lip, cheek or chin projection.
Our Skinboosters guide explains the wider category. This guide focuses on the named Profhilo products and how to interpret their evidence.
What does “bioremodeling” mean for a result?
Bioremodeling is the term used to describe this approach. It should lead to a clearer discussion of the intended result, rather than replace that discussion.
Separate three questions: what is proposed to happen in tissue, what a study actually measured, and what the participant noticed. A hydration reading, a wrinkle grade and satisfaction with appearance are different outcomes. A proposed effect on collagen does not tell you how much your face will change.
The collagen biostimulator guide covers a separate group of materials; its evidence should not be transferred to Profhilo because the treatments share some goals.
What have Profhilo studies found?
The examples below show why study design and the measured outcome matter. They are not a review of every published study, a ranking of treatments or evidence that all Profhilo formulations behave alike.
An early facial study: Sparavigna and Tenconi followed women treated with Profhilo for 16 weeks. Several clinical, instrumental and participant-reported measures improved. The study was open and had no untreated or placebo group, so it could not establish superiority over another treatment. IBSA supported the research. Original 2016 study.
A study in Singapore: Cheng and colleagues enrolled 30 Chinese women, with 26 participants contributing the main final assessments at week 12. Surface hydration improved, but only six participants had final hydration measurements. Some comparisons between visits for wrinkles, volume-loss ratings and elasticity were not statistically significant. There was no control group. Neoasia funded the study; IBSA supported medical writing, and two authors were IBSA employees. Original study, published online in 2025.
A controlled forehead study: A 2026 randomized trial involved 20 participants receiving a specific botulinum toxin A treatment, with or without added Profhilo. At the short-term follow-up, adding Profhilo did not produce a statistically significant advantage in the clinical or ultrasound assessments. The toxin was Massport, not Botox. The small study does not settle every possible use, but it does challenge the assumption that adding Profhilo always improves a plan. The authors declared no conflicts and nothing to report under funding. Original controlled trial.
These findings support a conversation about a particular outcome. “Improved skin quality” should not quietly become a promise of lifting, contour correction or a predictable degree of rejuvenation.
How long do results last?
There is no guaranteed duration for everyone. A study that follows participants for 12 or 16 weeks tells you about those visits; it does not establish the exact day an effect disappears or when every patient needs another treatment.
Before starting, ask what will be assessed, when the result will be reviewed and what would count as an insufficient response. The plan should distinguish the initial course from any later decision to repeat treatment. A published study schedule is not an individual prescription.
How to read before-and-after photographs
A useful comparison identifies the exact product, treated area, timing and any other procedures performed between photographs. Lighting, expression, camera distance and head position should also be comparable. The controlled forehead trial, for example, used standardized photographs and blinded assessors; a casual photograph does not provide the same information. Trial methods.
Ask what the images are intended to show: texture, wrinkles, hydration or contour. One person’s photograph cannot predict your result. It is also reasonable to ask what the treatment is expected to leave unchanged.
Suitability, side effects and warning signs
Discuss medical conditions, medicines, allergies and previous procedures before choosing an injectable. The manufacturer leaflets consulted contain restrictions concerning pregnancy, breastfeeding, autoimmune disease, inflamed treatment areas and certain combinations of procedures. The exact product instructions and your assessment govern the decision. Profhilo precautions, Structura precautions.
The leaflets list possible injection-site reactions including pain, redness, swelling, itching and bruising. Small studies cannot give precise reassurance about uncommon complications.
Facial injections also require attention to vascular risk. The FDA warns that accidental injection of filler into a blood vessel can damage tissue and cause visual or neurological injury. Unusual pain, vision changes, white, gray or blue skin, weakness or difficulty speaking require immediate medical attention. This general safety guidance is not evidence of U.S. approval for Profhilo. FDA safety information.
Questions to bring to an assessment
- Which exact product and presentation are you proposing, and why?
- What finding explains my concern, and what change is realistic?
- Which evidence applies to this area and goal?
- What alternatives, including no procedure, should I consider?
- What follow-up is planned, and who should I contact if there is a problem?
Ask to see the product’s name, manufacturer, batch, expiry and applicable instructions. A foreign leaflet does not replace checking the relevant local documentation.
For information about the existing clinic procedure, see Profhilo at Juvenalia Brío.